Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Data Reproducibility in Preclinical Discovery, Is It a Real Problem? 09/17/15


Published on

On Sep 17th Catalyst brought a panel of academic and industry thought leaders for a lively discussion on the issue of data reproducibility in academic research. Moderated by Cathy Tralau-Stewart, head of the Therapeutics track of the Catalyst Awards, the panel explored causes and potential solutions for a problem that has been receiving national attention in both scientific and popular media.

Panelists included Keith Yamamoto, Vice Chancellor for Research at UCSF; Larry Tabak, Principle Deputy Director, NIH; John Ioannidis, Professor of Health Research Policy at Stanford School of Medicine; Elizabeth Iorns, Co-Founder, Science Exchange; Parker B. Antin, Board of Directors President, FASEB; Amanda Halford, MBA, VP of Research, Sigma-Aldrich.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Data Reproducibility in Preclinical Discovery, Is It a Real Problem? 09/17/15

  1. 1. Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Data Reproducibility in Preclinical Discovery, Is it a Real Problem? Cathy Tralau-Stewart PhD FRSC Head, Therapeutics Track, UCSF Catalyst
  2. 2. Thank you to our sponsors
  3. 3. Why is Reproducibility Currently Hitting The Headlines ?
  4. 4. ‘The push to replicate findings could shelve promising research and unfairly damage the reputations of careful, meticulous scientists’ Mina Bissell 2013 ‘the challenge of increasing reproducibility and addressing the costs associated with the lack of reproducibility in life science research is simply too important and costly to ignore’. Freedman 2015 ‘the guidelines could make preparing, submitting and reviewing research papers more burdensome, and that the checklists and other requirements imposed by journals could make it more difficult to recruit high-quality peer reviewers’ Haywood 2015 ‘The recent evidence showing the irre- producibility of significant numbers of biomedical-research publications demands immediate and substantive action’ Collins & Tabak 2015 ‘Our observations indicate that literature data on potential drug targets should be viewed with caution’ Prinz et al 2014 The Debate
  5. 5. Potential Implications of Non Reproducibility Globally • Estimated $28bn wasted per year (50% of US Pre-Clinical spend) due to reproducibility issues • Reduction in; – products – Patient benefit – Return on Investment (ROI) – Innovation • Exposure of patients to ineffective or dangerous new drugs For The Research Community Proof of reproducibility may soon be a requirement for • Publication • Securing funding & Investment
  6. 6. Evidence for Poor Reproducibility Freedman LP et al PLOS 2015
  7. 7. ~50% of Annual US Pre-Clinical Research Spend Are Subject to Reproducibility Errors Freedman LP et al PLOS 2015
  8. 8. Cathy Tralau-Stewart, PhD Head, Therapeutics Track, UCSF Catalyst Moderator: UCSF–CTSI Catalyst Awards presents Data Reproducibility in Preclinical Discovery, Is it a Real Problem? Panelists: Keith Yamamoto, PhD Vice Chancellor for Research Executive Vice Dean, UCSF School of Medicine John Ioannidis, MD, DSc Professor of Health Research Policy Stanford School of Medicine Parker Antin, PhD FASEB Board of Directors President Amanda Halford, MBA VP of Academic Research Sigma-Aldrich Elizabeth Iorns, PhD Co-Founder & CEO Science Exchange Lawrence Tabak, DDS, PhD Principal Deputy Director NIH Questions for Panel: